Baxalta Races Full Steam Ahead Into 2016 With Hematology At The Fore
This article was originally published in Scrip
Executive Summary
Baxalta Inc. is "energized and optimistic" for the New Year and expects to continue building up a strong portfolio and research pipeline on the back of a successful first six months as an independent new business.
You may also be interested in...
Shire Snags EU Okay For Von Willebrand Drug Veyvondi
Although noises are still being made in Japan concerning the benefits of Shire's merger with Takeda, the former is going about the business of getting marketing green lights with the latest being for its inherited bleeding disorder treatment Veyvondi in Europe.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.